Brooks Lab.

Who are the top shareholders of the Brooks Lab.?

The top shareholders of Brooks Lab include Atul Ranchal with 19.24%, Quant Mutual Fund at 9.9%, and individual investors collectively holding 31.86%. Foreign institutional investors hold a minimal 0.05%.

The top shareholders of Brooks Lab include the promoters, with Atul Ranchal holding the highest individual stake at 19.24%. Additionally, Quant Mutual Fund, specifically through the Quant Business Cycle Fund, is the highest public shareholder with a holding of 9.9%. The company also has mutual funds holding 9.9% through one scheme and foreign institutional investors (FIIs) holding a minimal 0.05%. Individual investors collectively own 31.86% of the company.

how big is Brooks Lab.?

As of October 2023, Brooks Laboratories Ltd has a market capitalization of 393.70 Cr and reported net sales of 82.56 Cr with a net loss of 9.96 Cr over the last four quarters. Shareholder's funds are 65.59 Cr, and total assets amount to 90.45 Cr.

Market Cap: Brooks Laboratories Ltd has a market capitalization of 393.70 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which is consolidated data, amounts to 82.56 Cr. In contrast, the sum of Net Profit for the same period shows a loss of 9.96 Cr.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in March 2024. Shareholder's Funds are reported at 65.59 Cr, while Total Assets stand at 90.45 Cr.

Who are in the management team of Brooks Lab.?

As of March 2022, the management team of Brooks Lab includes Rajnish Kumar Bedi, Deepak Mahajan, and Sonia Gupta as Independent Directors, and Kaushalya Singh and Jitendra Pratap Singh as Whole Time Directors.

As of March 2022, the management team of Brooks Lab includes the following individuals:<BR><BR>1. Rajnish Kumar Bedi - Independent Director<BR>2. Deepak Mahajan - Independent Director<BR>3. Sonia Gupta - Independent Director<BR>4. Kaushalya Singh - Whole Time Director<BR>5. Jitendra Pratap Singh - Whole Time Director<BR><BR>These members play various roles within the company's governance and management structure.

What does Brooks Lab. do?

Brooks Laboratories Ltd is a pharmaceutical manufacturing company specializing in contract manufacturing of injectables, tablets, and dry syrups. As of March 2025, it reported net sales of 23 Cr and a net loss of 1 Cr, with a market cap of Rs 404 Cr.

Overview:<BR>Brooks Laboratories Ltd is a pharmaceutical manufacturing company operating in the Micro Cap segment of the Pharmaceuticals & Biotechnology industry, focusing on contract manufacturing of injectables, tablets, and dry syrups.<BR><BR>History:<BR>Brooks Laboratories Limited was incorporated on January 23, 2002. The company has been engaged in manufacturing for domestic customers and reported its latest quarterly results for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 23 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -1 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: Rs 404 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.06<BR>- Return on Equity: -10.15%<BR>- Price to Book: 4.14<BR><BR>Contact Details:<BR>Address: Village Kishanpura, Nilagarh Road Baddi Solan Himachal Pradesh : 174101<BR>Tel: 91-1795-654001/02/03<BR>Email: investors@brookslabs.net<BR>Website: http://www.brookslabs.net

Has Brooks Lab. declared dividend?

No Dividend History Available

Who are the peers of the Brooks Lab.?

Brooks Lab.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma. Brooks Lab. has below average management risk and growth, with a 1-year return of 83.44%, lower than Everest Organics' 252.60% but higher than Fredun Pharma's -8.48%.

Peers: The peers of Brooks Lab. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Everest Organics, SMS Lifesciences, Zenotech Lab., Fredun Pharma, and the rest. Below Average management risk is attributed to Brooks Lab. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, Zenotech Lab., and the rest. Average growth is noted at SMS Lifesciences, and good growth is observed at Fredun Pharma. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, while good capital structure is found at Torrent Pharma, average at SMS Lifesciences, and below average at Brooks Lab., Everest Organics, and Fredun Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the lowest is Fredun Pharma at -8.48%. Brooks Lab.'s 1-year return of 83.44% is significantly higher than Fredun Pharma's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Cipla, Torrent Pharma, and Fredun Pharma.

Is Brooks Lab. overvalued or undervalued?

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20 October 2025, the valuation grade for Brooks Lab. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on key financial metrics. The PE ratio stands at an exceptionally high 173.77, while the EV to EBITDA ratio is 46.27, both of which are significantly higher than its peers. In contrast, Sun Pharma has a PE ratio of 35.32 and an EV to EBITDA of 23.96, while Cipla, considered attractive, has a PE of 24.56 and an EV to EBITDA of 17.35.<BR><BR>Overall, Brooks Lab. appears to be overvalued given its high valuation ratios and poor financial performance, including a negative ROE of -10.15% and a low ROCE of 3.18%. Recent stock performance has also been disappointing, with a year-to-date decline of 35.25%, compared to a 7.97% increase in the Sensex, further reinforcing the notion that the stock is not a favorable investment at its current price of 119.75.

How has been the historical performance of Brooks Lab.?

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

Answer:<BR>The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar'25 from 90.45 Cr in Mar'24, while total liabilities also rose to 123.69 Cr in Mar'25, reflecting a stable financial position. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25, contrasting with negative cash flows in previous years, indicating a potential turnaround in operational efficiency.

When is the next results date for Brooks Laboratories Ltd?

The next results date for Brooks Laboratories Ltd is 06 February 2026.

The next results date for Brooks Laboratories Ltd is scheduled for 06 February 2026.

Are Brooks Laboratories Ltd latest results good or bad?

Brooks Laboratories Ltd's latest results are concerning, showing a 31.08% decline in net profit and a 29.34% drop in net sales, marking their weakest performance in eight quarters. The significant decline in operating margin and misleading profit after tax margin indicate serious operational challenges that investors should monitor closely.

The latest results for Brooks Laboratories Ltd are concerning and indicate significant operational challenges. In the quarter ending December 2025, the company reported a consolidated net profit of ₹5.50 crore, which represents a decline of 31.08% compared to the previous quarter. Additionally, net sales dropped sharply by 29.34% quarter-on-quarter to ₹16.57 crore, marking the weakest performance in eight quarters. <BR><BR>The operating margin also suffered, falling to 4.41%, the lowest level recorded in recent history, down from 10.75% in the previous quarter. This decline in profitability raises red flags about the company's operational efficiency and ability to sustain its business model.<BR><BR>Furthermore, the reported profit after tax margin of 33.19% is misleading as it was significantly influenced by tax adjustments rather than genuine operational performance. The underlying operational deterioration suggests that the company is facing serious challenges in maintaining its revenue and profitability.<BR><BR>Overall, the results can be characterized as bad, reflecting a troubling trend that investors should closely monitor.

Should I buy, sell or hold Brooks Laboratories Ltd?

Why is Brooks Laboratories Ltd falling/rising?

As of 16-Mar, Brooks Laboratories Ltd is facing a significant decline in its stock price, currently at Rs 56.23, with a 52-week low of Rs 55.09. The stock has underperformed against the Sensex across various time frames, showing high volatility and declining investor interest, while long-term fundamentals remain weak.

As of 16-Mar, Brooks Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 56.23, which reflects a change of -1.96 (-3.37%). The stock has hit a new 52-week low of Rs 55.09 today and has been on a downward trend, having fallen consecutively for the last two days, resulting in a total decline of -10.4% during this period. <BR><BR>The stock's performance over various time frames shows significant underperformance compared to the benchmark Sensex. Over the past week, Brooks Laboratories has decreased by -4.21%, while the Sensex fell only -2.66%. In the last month, the stock has dropped -24.83%, compared to a -9.34% decline in the Sensex. Year-to-date, the stock is down -29.93%, against an -11.40% drop in the benchmark. Over the past year, the stock has plummeted -44.63%, while the Sensex has gained +2.27%. <BR><BR>Today's trading session has been characterized by high volatility, with an intraday volatility of 9.36%. The stock opened with a loss of -2.05% and has traded within a wide range of Rs 7.99, indicating significant fluctuations in investor sentiment. Additionally, the stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which is typically a bearish signal.<BR><BR>Investor participation has also declined, with delivery volume falling by -20.69% compared to the 5-day average. This lack of interest from investors further contributes to the stock's downward pressure. <BR><BR>While the company has reported positive financial results over the last five quarters, including a significant increase in profits, the long-term fundamentals remain weak. The average Return on Equity (ROE) is low at 2.42%, and net sales growth has been modest at an annual rate of 3.87% over the last five years. Furthermore, the company's ability to service its debt is concerning, as indicated by a poor EBIT to Interest ratio of -2.37. <BR><BR>In summary, the combination of poor recent performance, high volatility, declining investor interest, and weak long-term fundamentals are contributing to the falling stock price of Brooks Laboratories Ltd.

Which are the latest news on Brooks Lab.?